全球医用大麻市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

医用大麻市场分析

近年来，医用大麻市场经历了显着增长，因为人们越来越认识到大麻对各种疾病的治疗益处。随着多个地区合法化努力的推进，对医用大麻产品的需求正在上升。这个市场涵盖了各种各样的产品，包括油、胶囊和食品，针对慢性疼痛、癫痫和精神健康障碍等疾病而量身定制。最近的发展，例如种植技术和提取工艺的进步，提高了产品质量和功效，进一步推动了市场扩张。此外，消费者意识和接受度的提高，再加上政府的支持性政策，是促成市场乐观前景的关键因素。随着研究不断揭示大麻的潜在益处，医用大麻市场将实现持续增长，为制药公司和医疗保健提供商提供新的机遇。

医用大麻市场规模

2023 年全球医用大麻市场规模价值 210.6 亿美元，预计到 2031 年将达到 1089 亿美元，2024 年至 2031 年预测期内的复合年增长率为 22.80%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

医用大麻市场趋势

“个性化大麻产品的需求”

医用大麻市场正在经历由创新和不断变化的消费者偏好推动的变革趋势。一个值得注意的趋势是消费者对个性化大麻产品的需求不断增长，消费者寻求定制配方来满足特定的健康状况和个人需求。大麻提取和配方技术的创新正在推动各种产品的开发，例如针对性油和浸泡食品，以增强治疗效果。此外，技术进步，包括在种植和供应链管理中使用人工智能和数据分析，正在优化生产流程并确保产品的一致性。总体而言，这些趋势反映了向更有效、定制化的医用大麻解决方案的转变，以满足患者的不同需求并推动市场增长。

报告范围和医用大麻市场细分  

Medical Cannabis Market Definition

Medical cannabis refers to the use of the cannabis plant and its derivatives for therapeutic purposes. It encompasses a variety of products, including oils, capsules, tinctures, and topical formulations, containing cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Medical cannabis is prescribed to alleviate symptoms associated with various health conditions, including chronic pain, epilepsy, multiple sclerosis, nausea from chemotherapy, and anxiety. Its use is often regulated by laws that vary by region, and it is typically recommended when conventional treatments have proven ineffective.

Medical Cannabis Market Dynamics

Drivers

• Increasing Acceptance and Legalization

The increasing acceptance of medical cannabis among healthcare professionals and medical cannabis patients is a significant driver of market growth. As research continues to unveil the therapeutic benefits of cannabinoids for various medical conditions, healthcare providers are more inclined to recommend cannabis as a treatment option. This shift in perception has led to greater patient awareness and willingness to consider medical cannabis for managing chronic pain, anxiety, and other ailments. Moreover, the legalization of medical cannabis in numerous regions has further facilitated its integration into mainstream healthcare. This regulatory change legitimizes its use and encourages investment in research and product development, thus expanding the market. The combined effect of these factors is expected to foster significant growth in the medical cannabis market.

•  Rising Prevalence of Chronic Diseases

The rising incidence of chronic diseases, including cancer, epilepsy, and multiple sclerosis, has created a substantial demand for effective pain management and therapeutic solutions, significantly boosting the medical cannabis market. Patients suffering from these conditions often experience severe pain, discomfort, and a range of debilitating symptoms that conventional treatments may not adequately address. Medical cannabis, with its diverse array of cannabinoids, offers a natural alternative that can alleviate pain and improve quality of life. As healthcare providers increasingly recognize the potential of cannabis-based treatments, more patients are being referred to medical cannabis as a viable option. This growing acceptance, alongside ongoing research demonstrating the efficacy of cannabis for symptom relief, continues to propel market growth as patients seek effective and holistic approaches to managing their health conditions.

Opportunities

• Integration with Traditional Healthcare

Collaborations between cannabis companies and traditional healthcare providers present a significant opportunity for market growth in the medical cannabis sector. By partnering with healthcare professionals, cannabis companies can enhance the legitimacy of their products and foster trust among potential patients. These collaborations can lead to the development of educational programs and clinical guidelines, making healthcare providers more comfortable recommending cannabis therapies as part of a comprehensive treatment plan. As healthcare providers gain confidence in the efficacy and safety of medical cannabis, they are more likely to advocate for its use, ultimately increasing patient access to these therapies. This integration broadens the market reach of cannabis products and contributes to the overall acceptance of medical cannabis within mainstream healthcare, driving sustained market expansion.

• Advancements in Research and Development

Ongoing research into the therapeutic benefits of cannabinoids is unlocking new opportunities in the medical cannabis market. As scientists and healthcare professionals continue to explore the medicinal properties of various cannabinoids, they are discovering innovative applications for conditions ranging from chronic pain and anxiety to neurological disorders. This research has led to the development of new medical cannabis products, expanding the variety of treatment options available to patients. Such advancements cater to diverse patient needs and enhance the efficacy and safety profiles of cannabis-based therapies. As more clinical studies validate the benefits of these products, they are likely to gain acceptance among healthcare providers and patients alike. This expansion of product offerings presents a lucrative opportunity for companies to capture a larger share of the growing medical cannabis market, ultimately improving patient outcomes and satisfaction.

Restraints/Challenges

• Lack of Standardized Regulations

The medical cannabis market faces significant challenges due to the lack of standardized regulations and the varying legal frameworks across different regions. Each jurisdiction has its own rules governing the cultivation, distribution, and sale of medical cannabis, creating a complex landscape for companies to navigate. This regulatory inconsistency often results in confusion and delays in market entry for new players. Companies may spend considerable time and resources understanding local laws, obtaining necessary licenses, and ensuring compliance with diverse regulations. These hurdles can deter potential investors and limit the growth of the market. Consequently, the absence of a unified regulatory approach poses a significant challenge to the expansion and accessibility of medical cannabis products globally.

•  Competition from Traditional Therapies

Established pharmaceutical treatments continue to hold a significant share of the healthcare market, often backed by extensive research, clinical trials, and regulatory approvals. These conventional therapies are widely prescribed by healthcare professionals and have a long-standing reputation for safety and efficacy. As a result, patients and doctors may be hesitant to consider medical cannabis products as viable alternatives, especially in serious conditions like cancer and chronic pain. The familiarity and trust in traditional medications can hinder the adoption of medical cannabis, despite its potential benefits. This reliance on established treatments limits the market growth for cannabis-based therapies, as healthcare professionals may prioritize familiar pharmaceutical options over newer, less understood cannabis products. This restraint creates a challenge for the medical cannabis market to gain traction among patients and healthcare providers.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Medical Cannabis Market Scope

The market is segmented on the basis of product, source, species, derivatives, application, route of administration, treatment type, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Oil
• Medical Cannabis Capsules
• Patch
• Whole Flower
• Ground Flower
• Vape Pen
• Dried Medical Cannabis
• Creams & Moisturizers
• Masks & Serum
• Cleanser
• Others

Source

• Natural
• Synthetic

Species

• Cannabis Indica
• Cannabis Sativa
• Hybrid

Application

• Alzheimer’s Disease
• Appetite Loss
• Cancer
• Inflammatory Bowel Diseases
• Eating Disorders
• Epilepsy
• Autism
• Mental Health Conditions
• Multiple Sclerosis
• Pain Management
• Nausea
• Muscle Spasms
• Wasting Syndrome (Cachexia)
• Elevate Mood
• Depression and Sleep Disorders
• Anxiety
• Others

Derivatives

• Cannabidiol (CBD)
• Tetrahydrocannabinol (THC) / Delta-8-Tetrahydrocannabinol
• Cannabinol (CBN)
• Cannabicyclol (CBL)
• Cannabichromene (CBC)
• Cannabigerol (CBG)
• Others

Treatment Type

• Expectorant
• Antiviral
• Analgesic
• Aphrodisiac
• Psychedelic
• Others

Route of Administration

• Oral Solutions and Capsules
• Smoking
• Vaporizers
• Topicals
• Others

End User

• Pharmaceutical Industry
• Research and Development Centers
• Homecare Setting
• Hospitals
• Rehab Centers
• Others

Distribution Channel

• B2B
• B2C

 Medical Cannabis Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, source, species, derivatives, application, route of administration, treatment type, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

由于医用大麻投资不断增加，北美有望主导全球医用大麻市场。由于医用大麻使用合法化，美国有望主导北美地区。由于新兴市场对医用大麻的需求不断增加和扩张，德国有望主导欧洲地区。由于拥有主要制造商和先进的技术工艺，澳大利亚有望主导亚太地区。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。  

医用大麻市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在市场上运营的医用大麻市场领导者是：

• MediPharm Labs Inc.（加拿大）
• Tilray（加拿大）
• Aurora Cannabis（加拿大）
• JAZZ Pharmaceuticals Inc.（英国）（GW Pharmaceuticals plc）
• HEXO Corp.（加拿大）（Zenabis Global Ltd）
• Cresco Labs（美国）
• Peace Naturals Project Inc.（加拿大）
• CANOPY GROWTH CORPORATION（加拿大）
• 医用大麻公司（美国）
• 种子窖（美国）
• EcoGen Biosciences（美国）
• 美国大麻种子（美国）
• Seeds For Me（美国）
• 洪堡种子公司（美国）
• Extractas（美国）
• 世界级大麻种子（Crop King Seeds）（加拿大）
• BARNEY'S FARM（荷兰）
• FOLIUM BIOSCIENCES（美国）
• PharmaHemp（英国）
• Elixinol Global Limited（澳大利亚）
• ENDOCA（荷兰）
• Harmony（英国）
• MARY'S Nutritionals, LLC（美国）
• 纯比率（美国）
• 格林威治生物科学公司（美国）
• 上州电梯供应公司 (美国)
• Apothecanna（美国）
• BOL Pharma（以色列）
• IDT 澳大利亚 (澳大利亚)

医用大麻市场的最新发展

• 2023 年 2 月，专门从事全球大麻分销的加拿大公司 Aurora Cannabis Inc. 与 MedReleaf Australia 合作，推出了面向澳大利亚市场的全新医用大麻品牌 CraftPlant。CraftPlant 的初始产品包括三款产品——Greendae、Navana 和 HiVolt——所有这些产品现在都可供医生开处方。每种菌株都具有高 THC 浓度，并来源于 Aurora 领先的科学和遗传学公司 Occo 开发的优质品种，并将包装在 10g 罐中，按照严格的欧盟 GMP 授权标准生产
• 2023 年 7 月，印度肿瘤学公司 Carer 宣布与经过认证的医用大麻和大麻二酚制造商 Wholeleaf 建立合作伙伴关系。此次合作旨在通过提供全面的支持来改善癌症患者的整体健康状况，包括护理人员的营养、物理治疗和心理健康服务。在获得印度卫生部正式批准在全国范围内生产和销售其产品后，CARER 和 Wholeleaf 正在整合他们的服务，为癌症护理提供整体解决方案
• 2023 年 9 月，因帮助澳大利亚人获取医用大麻而获得认可的诊所 Alternaleaf 宣布将业务扩展到英国。研究表明，在需求不断增长的推动下，英格兰有望成为欧洲第二大医用大麻市场。英国有超过 36 万例阿片类药物成瘾病例，专家认为医用大麻可以作为阿片类药物的可行替代品，而阿片类药物经常被不必要地开具
• 2022 年 4 月，Medi Cane Health Inc. 和 Dr. Reddy's Laboratories Ltd. 在德国推出了其医用大麻产品。此次合作旨在满足该地区对医用大麻解决方案日益增长的需求。该产品的推出标志着德国患者在扩大治疗性大麻选择方面迈出了重要一步
• 2022 年 4 月，纽约市首次出现合法大麻销售，而就在一个月前，七家医用大麻企业获准向所有成年人销售其产品。这一里程碑标志着该州大麻格局发生了重大转变，扩大了大麻的使用范围，而不仅仅是药用。该计划旨在创建一个受监管的市场，同时造福当地经济并确保消费者安全

SKU-52961